The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type II
- Registration Number
- NCT00131287
- Lead Sponsor
- ECbiotech Taiwan
- Brief Summary
The purpose of this study is to examine whether the extract of the Agaricus blazei Murill mushroom is effective in the supplementary treatment of type II DM patients.
- Detailed Description
The researchers have the animal model that the extract of the Agaricus blazei Murill mushroom is effective in the treatment of type II DM mice conducted on 2002. The dose effects were also found. The researchers conducted the pilot study also showing the same effects in 2003. So the researchers designed this trial. The elixir of the Agaricus blazei Murill mushroom is popular in Taiwan for chronic diseases, such as type II DM.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 108
Inclusion Criteria
- Type II DM
- Age 20-75 years old
- Treat with Gliclazide and Metformin
- Signed informed consent
Exclusion Criteria
- GOT/GPT >80/80
- Creatinine > 2.0
- Lactating or pregnant women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR)
- Secondary Outcome Measures
Name Time Method Glucose, cholesterol, triglyceride, leptin, adiponectin comparisons
Trial Locations
- Locations (1)
Chung-Hua Hsu
🇨🇳Taipei, Taiwan